Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29136188 | 0.86 | RAB9A (0.42) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3086229 | 0.86 | CYP1A2 (0.39) | RECQLTNF | |
| SCHEMBL3079067 | 0.86 | P2RX4 (0.44) | RECQLLMNASMN1; SMN2P2RX4KMT2A | |
| SCHEMBL29136204 | 0.82 | HTT (0.45) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3088019 | 0.82 | ALOX5AP (0.42) | SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3079977 | 0.82 | DRD2 (0.41) | SMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3091129 | 0.82 | P2RX4 (0.48) | LMNASMN1; SMN2P2RX4SIGMAR1ALDH1A1 | |
| SCHEMBL15271285 | 0.80 | RECQL (0.35) | RECQLKMT2AMEN1 | |
| SCHEMBL29136202 | 0.78 | KMT2A (0.55) | LMNASMN1; SMN2SIGMAR1KMT2AMEN1 | |
| SCHEMBL5327642 | 0.76 | CDK4 (0.33) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | claimed |
| US-7816368-B2 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2010-10-19 | — | — | US | claimed |
| US-20090042924-A1 | Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | claimed |
| US-7456193-B2 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-11-25 | — | — | US | claimed |
| EP-1863771-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | Transtech Pharma, Inc. (US) | 2007-12-12 | — | — | EP | claimed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | claimed |
| WO-2006099379-A2 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| EP-1556380-B1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2006-04-12 | — | — | EP | claimed |
| US-20050222192-A1 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-10-06 | — | — | US | claimed |
| EP-1556380-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | claimed |
| WO-2004037821-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-05-06 | — | — | WO | claimed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | claimed |
| EP-0299972-B1 | ANTHELMINTIC QUATERNARYALKYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1992-03-04 | — | — | EP | claimed |
| EP-0299972-A1 | ANTHELMINTIC QUATERNARYALKYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS. | UPJOHN CO (US) | 1989-01-25 | — | — | EP | claimed |
| WO-1987006132-A1 | ANTHELMINTIC QUATERNARYALKYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS | THE UPJOHN COMPANY (US) | 1987-10-22 | — | — | WO | claimed |
| US-9597316-B2 | Indole compounds for use in treating inflammation and cancer | BIOVENTURES LLC (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150328216-A1 | INDOLE COMPOUNDS FOR USE IN TREATING INFLAMMATION AND CANCER | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2015-11-19 | — | — | US | disclosed |
| US-4065427-A | Polychromophoric heterocyclic ultraviolet stabilizers and their use in organic compositions | EASTMAN KODAK COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4017508-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-4000148-A | POLYMERS | EASTMAN KODAK COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222192-A1 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | CBR3, PNPO, CBR1 | RECQL 1219/4885CYP19A1 1391/4885LMNA 1216/4885 |
| US-20150328216-A1 | INDOLE COMPOUNDS FOR USE IN TREATING INFLAMMATION AND CANCER | TUBB1, IDO2, PTGS2 | RECQL 3657/4885CYP19A1 2049/4885LMNA 3319/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | RECQL 3081/4885CYP19A1 794/4885LMNA 679/4885 |
| US-20090042924-A1 | Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics | PNPO, DPYD, PDXK | RECQL 75/4885CYP19A1 925/4885LMNA 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.